Basal cell carcinoma screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Basal cell carcinoma}} | {{Basal cell carcinoma}} | ||
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D. | {{CMG}} {{AE}} Saarah T. Alkhairy, M.D.,{{M.N}} | ||
==Overview== | ==Overview== | ||
| Line 8: | Line 8: | ||
==Basal Carcinoma Screening== | ==Basal Carcinoma Screening== | ||
*The U.S Preventive Task Force has found no [[evidence]] to recommend for or against [[screening]]<ref>{{cite journal|title=Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=150|issue=3|year=2009|pages=188|issn=0003-4819|doi=10.7326/0003-4819-150-3-200902030-00008}}</ref>. | *The U.S Preventive Task Force has found no [[evidence]] to recommend for or against [[screening]]<ref>{{cite journal|title=Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=150|issue=3|year=2009|pages=188|issn=0003-4819|doi=10.7326/0003-4819-150-3-200902030-00008}}</ref>. | ||
:*Task Force members state that “[[clinicians]] should remain [[alert]] for [[skin lesions]] with [[malignant]] [[Features (pattern recognition)|features]] noted in the context of [[Physical examination|physical examinations]] performed for other purposes,” and recognize that “even without formal [[screening]] programs, mortality from basal cell and [[squamous cell carcinoma]] is low compared with [[mortality]] from [[melanoma]], but early detection and treatment may reduce [[morbidity]] and disfigurement from these [[cancers]].” | :*Task Force members state that “[[clinicians]] should remain [[alert]] for [[skin lesions]] with [[malignant]] [[Features (pattern recognition)|features]] noted in the context of [[Physical examination|physical examinations]] performed for other purposes,” and recognize that “even without formal [[screening]] programs, [[mortality]] from basal cell and [[squamous cell carcinoma]] is low compared with [[mortality]] from [[melanoma]], but early detection and treatment may reduce [[morbidity]] and [[disfigurement]] from these [[cancers]].” | ||
*The [[American Cancer Society]] recommends that a [[health care]] provider examine the [[skin]] every year if the [[patient]] is older than 40 years, and every 3 years if the [[patient]] is between 20-40 years | *The [[American Cancer Society]] recommends that a [[health care]] provider examine the [[skin]] every year if the [[patient]] is older than 40 years, and every 3 years if the [[patient]] is between 20-40 years | ||
| Line 15: | Line 15: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 15:04, 6 March 2019
|
Basal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Basal cell carcinoma screening On the Web |
|
American Roentgen Ray Society Images of Basal cell carcinoma screening |
|
Risk calculators and risk factors for Basal cell carcinoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D., Maneesha Nandimandalam, M.B.B.S.[2]
Overview
The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening. The American Cancer Society recommends that a health care provider examine the skin every year if the patient is older than 40 years, and every 3 years if the patient is between 20-40 years.
Basal Carcinoma Screening
- Task Force members state that “clinicians should remain alert for skin lesions with malignant features noted in the context of physical examinations performed for other purposes,” and recognize that “even without formal screening programs, mortality from basal cell and squamous cell carcinoma is low compared with mortality from melanoma, but early detection and treatment may reduce morbidity and disfigurement from these cancers.”
- The American Cancer Society recommends that a health care provider examine the skin every year if the patient is older than 40 years, and every 3 years if the patient is between 20-40 years
References
- ↑ "Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 150 (3): 188. 2009. doi:10.7326/0003-4819-150-3-200902030-00008. ISSN 0003-4819.